company background image
DUL logo

Alnylam Pharmaceuticals DB:DUL Stock Report

Last Price

€260.50

Market Cap

€33.9b

7D

18.8%

1Y

93.8%

Updated

24 Mar, 2025

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

DB:DUL Stock Report

Market Cap: €33.9b

DUL Stock Overview

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. More details

DUL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 67.3% below our estimate of its fair value

Earnings are forecast to grow 58.08% per year

Earnings have grown 15.8% per year over the past 5 years

Risk Analysis

Significant insider selling over the past 3 months


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alnylam Pharmaceuticals, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€470.6m

Bayer

XTRA:BAYN

€23.7b

Merck KGaA

XTRA:MRK

€57.1b

Price History & Performance

Summary of share price highs, lows and changes for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$260.50
52 Week HighUS$276.90
52 Week LowUS$132.70
Beta0.39
1 Month Change8.45%
3 Month Change11.23%
1 Year Change93.82%
3 Year Change75.66%
5 Year Change175.87%
Change since IPO5,216.33%

Recent News & Updates

Recent updates

Shareholder Returns

DULDE BiotechsDE Market
7D18.8%0.4%-1.3%
1Y93.8%-14.3%13.1%

Return vs Industry: DUL exceeded the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: DUL exceeded the German Market which returned 13.3% over the past year.

Price Volatility

Is DUL's price volatile compared to industry and market?
DUL volatility
DUL Average Weekly Movement6.7%
Biotechs Industry Average Movement9.1%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.1%
10% least volatile stocks in DE Market2.8%

Stable Share Price: DUL has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: DUL's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,230Yvonne Greenstreetwww.alnylam.com

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
DUL fundamental statistics
Market cap€33.90b
Earnings (TTM)-€257.10m
Revenue (TTM)€2.08b

16.3x

P/S Ratio

-131.9x

P/E Ratio

Is DUL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DUL income statement (TTM)
RevenueUS$2.25b
Cost of RevenueUS$323.37m
Gross ProfitUS$1.92b
Other ExpensesUS$2.20b
Earnings-US$278.16m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.15
Gross Margin85.62%
Net Profit Margin-12.37%
Debt/Equity Ratio3,684.7%

How did DUL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 12:43
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 60 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg